Truist Lifts Immunovant (IMVT) PT to $22 on Updated 2026 Financial Modeling

Immunovant Inc. (NASDAQ:IMVT) is one of the promising stocks to buy under $50. On January 8, Truist analyst Danielle Brill raised the firm’s price target on Immunovant to $22 from $16, while maintaining a Hold rating on the shares. While the firm updated its financial model, Truist informed investors that its core fundamental outlook remains unchanged from 2025. On January 6, Wolfe Research upgraded Immunovant from Peer Perform to Outperform with a $50 price target and noted a shift in market sentiment r ...